|
||
| |||||||
|
GSK extends agreement with Peakdale for discovery research
Chapel-en-le-Frith, UK, 22nd April 2005 – Peakdale Molecular
announces the extension of its agreement with GlaxoSmithKline (GSK) to provide
ongoing services for the Respiratory and Inflammation Centre of Excellence for
Drug Discovery (RI CEDD).
Under the
extension of the agreement through 2005, GSK continues to make use of
Peakdale's synthetic chemistry abilities, and have expanded the agreement to
include support for GSK’s Cardiovascular and Urogenital (CVU) CEDD.
Kim Morrison,
Peakdale CEO, commented, “Peakdale is known for its abilities to devise new
synthetic routes to challenging compounds in a flexible and responsive
service, delivering on time and in full. This revised agreement gives GSK
continuation of a dedicated team of chemists for the duration of the
projects.”
Copy ends
About
Peakdale Molecular
Peakdale Molecular was founded in 1992. Today, the Company’s customers include global pharmaceutical majors and an increasing number of biotechnology companies. Its team of chemists combines experience in pharmaceutical R&D and process development, fine chemicals, parallel synthesis and medicinal chemistry to deliver unique chemistry solutions to a range of drug discovery challenges. Peakdale operates in several distinct markets providing novel screening compounds, GPCR-targeted libraries, catalogue intermediates, custom synthesis and contract research chemistry. Further information about the Company can be obtained at www.peakdale.co.uk.
Enquiries:
Dr Gareth Jenkins Peakdale Molecular Tel: +44 (0) 1298 816700 Email: gareth.jenkins@peakdale.co.uk
Media
Enquiries:
Dr Marc Egelhofer Northbank Communications Tel: +44 (0) 1260 296500 Email: m.egelhofer@northbankcommunications.com |
|
| ||||||||